Expression of TPD52 protein in paraffin sections of lymphomas
Type . | Cases, N = 180 . | TPD52 expression by tumor cells* . |
|---|---|---|
| B-cell derived | ||
| Acute lymphoblastic leukemia | 30 | 6/30 |
| Chronic lymphocytic leukemia | 8 | 7/8 |
| Hairy cell leukemia | 10 | 10/10 |
| Mantle cell lymphoma | 5 | 5/5 |
| Marginal zone lymphoma | 5 | 4/5 |
| FCC lymphoma | 15 | 15/15 |
| DLCL-B | 20 | 15/20 |
| Burkitt lymphoma | 2 | 2/2 |
| Plasma cell tumors | 20 | 20/20† |
| T-cell derived | ||
| Lymphoblastic/T-ALL | 15 | 6/15 |
| Anaplastic large cell lymphoma | 10 | 0/10 |
| Other PTCL | 16 | 0/16 |
| Hodgkin lymphoma | ||
| Nodular sclerosis | 14 | 6/14‡ |
| Mixed cellularity | 9 | 3/9‡ |
| NLPHD | 1 | 1/1 |
Type . | Cases, N = 180 . | TPD52 expression by tumor cells* . |
|---|---|---|
| B-cell derived | ||
| Acute lymphoblastic leukemia | 30 | 6/30 |
| Chronic lymphocytic leukemia | 8 | 7/8 |
| Hairy cell leukemia | 10 | 10/10 |
| Mantle cell lymphoma | 5 | 5/5 |
| Marginal zone lymphoma | 5 | 4/5 |
| FCC lymphoma | 15 | 15/15 |
| DLCL-B | 20 | 15/20 |
| Burkitt lymphoma | 2 | 2/2 |
| Plasma cell tumors | 20 | 20/20† |
| T-cell derived | ||
| Lymphoblastic/T-ALL | 15 | 6/15 |
| Anaplastic large cell lymphoma | 10 | 0/10 |
| Other PTCL | 16 | 0/16 |
| Hodgkin lymphoma | ||
| Nodular sclerosis | 14 | 6/14‡ |
| Mixed cellularity | 9 | 3/9‡ |
| NLPHD | 1 | 1/1 |
The expression of TPD52 protein in paraffin sections of lymphomas was assessed using the B28p mAb. FCC indicates follicular lymphoma; DLCL-B, diffuse large B-cell lymphoma; PTCL, peripheral T-cell lymphoma; and NLPHD, nodular lymphocyte predominance Hodgkin lymphoma.
In all positive cells reactivity was cytoplasmic
Multiple myeloma (n = 16); solitary plasmocytoma of bone (n = 4)
Twenty percent to 80% positive tumor cells. One mixed-cellularity case was previously misdiagnosed as ALK-negative anaplastic large cell lymphoma (see “Results” and “Discussion”)